The Psoriatic Arthritis Treatment Market size was USD 9.97 Billion in 2023 and is expected to Reach USD 24.87 Billion by 2031 and grow at a CAGR of 12.1% over the forecast period of 2024-2031.
The Psoriatic Arthritis Treatment Market refers to the pharmaceutical and healthcare sector dedicated to developing and providing treatment options for psoriatic arthritis (PsA). Psoriatic arthritis is a chronic autoimmune disease that affects the joints and skin, causing inflammation, pain, and stiffness. It is often associated with psoriasis, a skin condition characterized by red, scaly patches. The Psoriatic Arthritis Treatment Market encompasses a wide range of therapies and medications aimed at managing the symptoms and slowing down the progression of the disease.
Get more information on Psoriatic Arthritis Treatment Market - Request Sample Report
These treatments can include Nonsteroidal anti-inflammatory drugs (NSAIDs) are medications that help reduce pain and inflammation associated with PsA. Disease-modifying antirheumatic drugs (DMARDs) are used to slow down the progression of joint damage and reduce symptoms. Examples include methotrexate, sulfasalazine, and leflunomide. Biologic agents are Biologic drugs, such as tumour necrosis factor (TNF) inhibitors, interleukin inhibitors, and Janus kinase (JAK) inhibitors, which target specific molecules involved in the immune system response. They help reduce inflammation and joint damage in PsA. Corticosteroids are in some cases, targeting corticosteroid injections that may be used to relieve severe joint inflammation and pain. Topical treatments are Topical creams, ointments, and lotions containing corticosteroids, salicylic acid, or vitamin D analogues can be used to manage psoriasis symptoms on the skin. Physical therapy and exercise programs can help improve joint mobility, reduce pain, and strengthen muscles.
The Psoriatic Arthritis Treatment Market is driven by the increasing prevalence of psoriatic arthritis worldwide and the growing demand for effective and personalized treatment options. Pharmaceutical companies invest in research and development to discover innovative therapies and improve existing treatment options. The market also includes diagnostic tools and monitoring devices to assess disease activity and response to treatment. It's important to note that market dynamics and specific treatment options may evolve over time, so it's recommended to consult up-to-date medical resources and healthcare professionals for the latest information on PsA treatment.
DRIVERS:
An enormous number of people worldwide are afflicted by the autoimmune illness psoriatic arthritis, which is rather frequent.
The growing Psoriasis Population is the major driver of this market.
Psoriatic arthritis often coexists with psoriasis, a chronic skin condition. As the prevalence of psoriasis continues to rise, the number of patients at risk of developing psoriatic arthritis also increases. This has created a larger patient pool requiring appropriate treatment for both conditions.
RESTRAIN:
Biologic drugs and tailored therapy are just two examples of cutting-edge psoriatic arthritis treatment alternatives that might be pricey.
The major bottleneck in this sector is a lack of awareness and underdiagnosis.
Psoriatic arthritis is still sometimes improperly or inadequately diagnosed. Accurate diagnosis and the start of the right therapy might be delayed by a lack of understanding among healthcare professionals and the general public. To address this issue and guarantee early detection and response, better education and awareness programmes are required.
OPPORTUNITY:
There is a chance to improve patient education and knowledge of psoriatic arthritis and the available treatments.
The largest opportunity in this sector is personalised medicine and precision treatment.
Customising treatment plans for specific individuals is now possible because to the increased emphasis on personalised medicine. The selection of treatments and dosage regimens can be improved by healthcare professionals by identifying biomarkers, genetic variables, and illness subtypes. This strategy may result in more effective treatments and happier patients.
CHALLENGES:
When it comes to clinical symptoms and disease severity, psoriatic arthritis is a very diverse illness that affects different people in different ways.
In this sector, treatment resistance and non-response are major obstacles.
While the majority of patients benefit from the current treatment choices, others suffer from treatment resistance or poor response. In order to improve outcomes for non-responders, this problem emphasises the need for alternate treatment techniques, such as researching novel pharmacological targets, combination therapy, and individualised methods.
The ongoing Russia-Ukraine conflict may have an effect on the Indian pharmaceutical industry given that the vast majority of local businesses are well-represented in both countries. Pharmaceutical products are India's biggest export to Ukraine. India is really the third-largest supplier of medications to Ukraine, after only Germany and France. For Indian pharmaceutical behemoths like Dr Reddy's Laboratories and Sun Pharma, the markets in Russia and Ukraine are significant. Russian revenues totalled Rs 5.1 billion, according to Dr Reddy's Laboratories' consolidated financial statements for the end of 2021. Revenues from newly introduced items, a favourable exchange rate, and a rise in the pricing of certain of its products all contributed to the 6% year-over-year growth, which was somewhat offset by a decline in sales volumes in its core business.
From the information given above, it can be inferred that growth can also be seen in the psoriatic arthritis treatment market.
IMPACT OF ONGOING RECESSION
In today's world, the pharmaceutical business is essential. The industry has grown into one of the most sophisticated industries since the Covid-19 epidemic and has continued to acquire prominence. To make sure that the medicines are both safe and efficient for patients and in accordance with changing market needs, it is always trying to develop and use innovative technology for drug trials. Economic shocks and recessions have little effect on pharmaceutical and biotech enterprises. For instance, national healthcare spending in the US increased as a percentage of GDP during previous recessions.
In a continual effort to allay concerns about a recession, the US Federal Reserve increased interest rates for the seventh time this year. The tightening of monetary and financial conditions, according to the International Monetary Fund, would cause the real gross domestic product (GDP) growth in the US to decline from 2.1% in 2022 to 1.4% in 2023. In addition, a number of financial organisations, including Bank of America and JP Morgan, have been predicting a slight US recession in 2023 for months. Small and mid-sized businesses (SMEs) are likely to be severely hit in the pharmaceutical industry. The psoriatic Arthritis treatment market is a huge market that why less impact of the ongoing recession on this market.
By Drugs Class
Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Others
By Route of Administration
Topical
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
REGIONAL ANALYSIS
North America: Due to a number of factors, North America is anticipated to dominate the psoriatic arthritis treatment market. One of the main causes of this is the region's rising rates of obesity and psoriatic arthritis, which have raised public awareness of the problem. In 2021, the Centres for Disease Control and Prevention (CDC) announced that adult obesity rates are rising in the US, with twelve states reporting prevalence rates of 34-36% or greater.
Asia Pacific: Due to rising knowledge of psoriatic arthritis treatment and increased acceptance of psoriatic arthritis treatment products, Asia-Pacific offers attractive prospects for major companies operating in the psoriatic arthritis treatment market. Additionally, it is anticipated that improvements in the healthcare infrastructure, an increase in the number of hospitals with cutting-edge medical equipment, the development of the R&D sector, an increase in healthcare reforms, and technological developments in the healthcare industry will have a significant impact on market growth. The presence of a sizable population base and the increased focus of major manufacturers on increasing their geographic presence in developing Asia-Pacific nations to seize high growth opportunities are anticipated to fuel the growth of the psoriatic arthritis treatment market in the region.
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Some major players in Psoriatic Arthritis Treatment Market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca, Abbvie Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Ampio Pharmaceuticals Inc., Amgen Inc., Merck & Co Inc., Boehringer Ingelheim International GmbH and other players.
In 2022: Over 50% of adult psoriatic arthritis patients receiving Skyrizi (risankizumab, 150mg) demonstrated a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and an American College of Rheumatology 20 (ACR20) response at 100 weeks, according to significant long-term data from the KEEPsAKE trials. These outcomes show how well Skyrizi works to treat psoriatic arthritis.
In 2022: Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, has been approved by the United States Food and Drug Administration (USFDA) for the treatment of people with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Given that Deucravacitinib may eventually provide patients with psoriatic arthritis with a new treatment choice, its approval marks a critical turning point for the industry.
| Report Attributes | Details |
| Market Size in 2023 | US$ 9.97 Bn |
| Market Size by 2031 | US$ 24.87 Bn |
| CAGR | CAGR of 12.1 % From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drugs Class (Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Others) • By Route of Administration (Topical, Oral, and Parenteral) • By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Sun Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca, Abbvie Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Ampio Pharmaceuticals Inc., Amgen Inc., Merck & Co Inc., Boehringer Ingelheim International GmbH |
| Key Drivers | • An enormous number of people worldwide are afflicted by the autoimmune illness psoriatic arthritis, which is rather frequent. • The growing Psoriasis Population is the major driver of this market. |
| Market Restraints | • Biologic drugs and tailored therapy are just two examples of cutting-edge psoriatic arthritis treatment alternatives that might be pricey. • The major bottleneck in this sector is a lack of awareness and underdiagnosis. |
Ans. The Compound Annual Growth rate for Psoriatic Arthritis Treatments Market over the forecast period is 12.1%.
Ans. USD 24.87 Billion is the projected Psoriatic Arthritis Treatments market size of the market by 2031.
Ans. Currently, the biologics sector leads the global market for treating psoriatic arthritis, and it is predicted that this trend will continue over the projection period.
Ans. In 2023, North America will have the largest share.
Ans. Psoriatic arthritis is becoming more common, biological and biosimilar medicines are becoming more popular, and research and development efforts to provide new medications to treat psoriatic arthritis are exploding. Increased elderly population, rising psoriatic arthritis treatment demand, and a robust pipeline of biosimilar and biologic medicines.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Psoriatic Arthritis Treatment Market Segmentation, By Drugs Class
8.1 Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
8.2 Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
8.3 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8.4 Others
9. Psoriatic Arthritis Treatment Market Segmentation, By Route of Administration
9.1 Topical
9.2 Oral
9.3 Parenteral
10. Psoriatic Arthritis Treatment Market Segmentation, By Distribution Channel
10.1 Hospital Pharmacies
10.2 Online Pharmacies
10.3 Retail Pharmacies
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Psoriatic Arthritis Treatment Market by Country
11.2.2 North America Psoriatic Arthritis Treatment Market by Drugs Class
11.2.3 North America Psoriatic Arthritis Treatment Market by Route of Administration
11.2.4 North America Psoriatic Arthritis Treatment Market by Distribution Channel
11.2.5 USA
11.2.5.1 USA Psoriatic Arthritis Treatment Market by Drugs Class
11.2.5.2 USA Psoriatic Arthritis Treatment Market by Route of Administration
11.2.5.3 USA Psoriatic Arthritis Treatment Market by Distribution Channel
11.2.6 Canada
11.2.6.1 Canada Psoriatic Arthritis Treatment Market by Drugs Class
11.2.6.2 Canada Psoriatic Arthritis Treatment Market by Route of Administration
11.2.6.3 Canada Psoriatic Arthritis Treatment Market by Distribution Channel
11.2.7 Mexico
11.2.7.1 Mexico Psoriatic Arthritis Treatment Market by Drugs Class
11.2.7.2 Mexico Psoriatic Arthritis Treatment Market by Route of Administration
11.2.7.3 Mexico Psoriatic Arthritis Treatment Market by Distribution Channel
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Psoriatic Arthritis Treatment Market by Country
11.3.1.2 Eastern Europe Psoriatic Arthritis Treatment Market by Drugs Class
11.3.1.3 Eastern Europe Psoriatic Arthritis Treatment Market by Route of Administration
11.3.1.4 Eastern Europe Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.1.5 Poland
11.3.1.5.1 Poland Psoriatic Arthritis Treatment Market by Drugs Class
11.3.1.5.2 Poland Psoriatic Arthritis Treatment Market by Route of Administration
11.3.1.5.3 Poland Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.1.6 Romania
11.3.1.6.1 Romania Psoriatic Arthritis Treatment Market by Drugs Class
11.3.1.6.2 Romania Psoriatic Arthritis Treatment Market by Route of Administration
11.3.1.6.4 Romania Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.1.7 Turkey
11.3.1.7.1 Turkey Psoriatic Arthritis Treatment Market by Drugs Class
11.3.1.7.2 Turkey Psoriatic Arthritis Treatment Market by Route of Administration
11.3.1.7.3 Turkey Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Psoriatic Arthritis Treatment Market by Drugs Class
11.3.1.8.2 Rest of Eastern Europe Psoriatic Arthritis Treatment Market by Route of Administration
11.3.1.8.3 Rest of Eastern Europe Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2 Western Europe
11.3.2.1 Western Europe Psoriatic Arthritis Treatment Market by Country
11.3.2.2 Western Europe Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.3 Western Europe Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.4 Western Europe Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.5 Germany
11.3.2.5.1 Germany Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.5.2 Germany Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.5.3 Germany Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.6 France
11.3.2.6.1 France Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.6.2 France Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.6.3 France Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.7 UK
11.3.2.7.1 UK Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.7.2 UK Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.7.3 UK Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.8 Italy
11.3.2.8.1 Italy Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.8.2 Italy Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.8.3 Italy Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.9 Spain
11.3.2.9.1 Spain Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.9.2 Spain Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.9.3 Spain Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.10 Netherlands
11.3.2.10.1 Netherlands Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.10.2 Netherlands Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.10.3 Netherlands Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.11 Switzerland
11.3.2.11.1 Switzerland Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.11.2 Switzerland Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.11.3 Switzerland Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.1.12 Austria
11.3.2.12.1 Austria Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.12.2 Austria Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.12.3 Austria Psoriatic Arthritis Treatment Market by Distribution Channel
11.3.2.13 Rest of Western Europe
11.3.2.13.1 Rest of Western Europe Psoriatic Arthritis Treatment Market by Drugs Class
11.3.2.13.2 Rest of Western Europe Psoriatic Arthritis Treatment Market by Route of Administration
11.3.2.13.3 Rest of Western Europe Psoriatic Arthritis Treatment Market by Distribution Channel
11.4 Asia-Pacific
11.4.1 Asia-Pacific Psoriatic Arthritis Treatment Market by Country
11.4.2 Asia-Pacific Psoriatic Arthritis Treatment Market by Drugs Class
11.4.3 Asia-Pacific Psoriatic Arthritis Treatment Market by Route of Administration
11.4.4 Asia-Pacific Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.5 China
11.4.5.1 China Psoriatic Arthritis Treatment Market by Drugs Class
11.4.5.2 China Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.5.3 China Psoriatic Arthritis Treatment Market by Route of Administration
11.4.6 India
11.4.6.1 India Psoriatic Arthritis Treatment Market by Drugs Class
11.4.6.2 India Psoriatic Arthritis Treatment Market by Route of Administration
11.4.6.3 India Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.7 japan
11.4.7.1 Japan Psoriatic Arthritis Treatment Market by Drugs Class
11.4.7.2 Japan Psoriatic Arthritis Treatment Market by Route of Administration
11.4.7.3 Japan Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.8 South Korea
11.4.8.1 South Korea Psoriatic Arthritis Treatment Market by Drugs Class
11.4.8.2 South Korea Psoriatic Arthritis Treatment Market by Route of Administration
11.4.8.3 South Korea Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.9 Vietnam
11.4.9.1 Vietnam Psoriatic Arthritis Treatment Market by Drugs Class
11.4.9.2 Vietnam Psoriatic Arthritis Treatment Market by Route of Administration
11.4.9.3 Vietnam Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.10 Singapore
11.4.10.1 Singapore Psoriatic Arthritis Treatment Market by Drugs Class
11.4.10.2 Singapore Psoriatic Arthritis Treatment Market by Route of Administration
11.4.10.3 Singapore Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.11 Australia
11.4.11.1 Australia Psoriatic Arthritis Treatment Market by Drugs Class
11.4.11.2 Australia Psoriatic Arthritis Treatment Market by Route of Administration
11.4.11.3 Australia Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Psoriatic Arthritis Treatment Market by Drugs Class
11.4.12.2 Rest of Asia-Pacific Psoriatic Arthritis Treatment Market by Route of Administration
11.4.12.3 Rest of Asia-Pacific Psoriatic Arthritis Treatment Market by Distribution Channel
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Psoriatic Arthritis Treatment Market by Country
11.5.1.2 Middle East Psoriatic Arthritis Treatment Market by Drugs Class
11.5.1.3 Middle East Psoriatic Arthritis Treatment Market by Route of Administration
11.5.1.4 Middle East Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.1.5 UAE
11.5.1.5.1 UAE Psoriatic Arthritis Treatment Market by Drugs Class
11.5.1.5.2 UAE Psoriatic Arthritis Treatment Market by Route of Administration
11.5.1.5.3 UAE Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.1.6 Egypt
11.5.1.6.1 Egypt Psoriatic Arthritis Treatment Market by Drugs Class
11.5.1.6.2 Egypt Psoriatic Arthritis Treatment Market by Route of Administration
11.5.1.6.3 Egypt Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Psoriatic Arthritis Treatment Market by Drugs Class
11.5.1.7.2 Saudi Arabia Psoriatic Arthritis Treatment Market by Route of Administration
11.5.1.7.3 Saudi Arabia Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.1.8 Qatar
11.5.1.8.1 Qatar Psoriatic Arthritis Treatment Market by Drugs Class
11.5.1.8.2 Qatar Psoriatic Arthritis Treatment Market by Route of Administration
11.5.1.8.3 Qatar Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Psoriatic Arthritis Treatment Market by Drugs Class
11.5.1.9.2 Rest of Middle East Psoriatic Arthritis Treatment Market by Route of Administration
11.5.1.9.3 Rest of Middle East Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.2 Africa
11.5.2.1 Africa Psoriatic Arthritis Treatment Market by Country
11.5.2.2 Africa Psoriatic Arthritis Treatment Market by Drugs Class
11.5.2.3 Africa Psoriatic Arthritis Treatment Market by Route of Administration
11.5.2.4 Africa Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Psoriatic Arthritis Treatment Market by Drugs Class
11.5.2.5.2 Nigeria Psoriatic Arthritis Treatment Market by Route of Administration
11.5.2.5.3 Nigeria Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.2.6 South Africa
11.5.2.6.1 South Africa Psoriatic Arthritis Treatment Market by Drugs Class
11.5.2.6.2 South Africa Psoriatic Arthritis Treatment Market by Route of Administration
11.5.2.6.3 South Africa Psoriatic Arthritis Treatment Market by Distribution Channel
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Psoriatic Arthritis Treatment Market by Drugs Class
11.5.2.7.2 Rest of Africa Psoriatic Arthritis Treatment Market by Route of Administration
11.5.2.7.3 Rest of Africa Psoriatic Arthritis Treatment Market by Distribution Channel
11.6 Latin America
11.6.1 Latin America Psoriatic Arthritis Treatment Market by Country
11.6.2 Latin America Psoriatic Arthritis Treatment Market by Drugs Class
11.6.3 Latin America Psoriatic Arthritis Treatment Market by Route of Administration
11.6.4 Latin America Psoriatic Arthritis Treatment Market by Distribution Channel
11.6.5 Brazil
11.6.5.1 Brazil America Psoriatic Arthritis Treatment Market by Drugs Class
11.6.5.2 Brazil America Psoriatic Arthritis Treatment Market by Route of Administration
11.6.5.3 Brazil America Psoriatic Arthritis Treatment Market by Distribution Channel
11.6.6 Argentina
11.6.6.1 Argentina America Psoriatic Arthritis Treatment Market by Drugs Class
11.6.6.2 Argentina America Psoriatic Arthritis Treatment Market by Route of Administration
11.6.6.3 Argentina America Psoriatic Arthritis Treatment Market by Distribution Channel
11.6.7 Colombia
11.6.7.1 Colombia America Psoriatic Arthritis Treatment Market by Drugs Class
11.6.7.2 Colombia America Psoriatic Arthritis Treatment Market by Route of Administration
11.6.7.3 Colombia America Psoriatic Arthritis Treatment Market by Distribution Channel
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Psoriatic Arthritis Treatment Market by Drugs Class
11.6.8.2 Rest of Latin America Psoriatic Arthritis Treatment Market by Route of Administration
11.6.8.3 Rest of Latin America Psoriatic Arthritis Treatment Market by Distribution Channel
12. Company Profile
12.1 Sun Pharmaceutical Industries Ltd
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Pfizer Inc.
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 AstraZeneca
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Abbvie Inc
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Teva Pharmaceuticals Industries Ltd.
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Novartis AG
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Ampio Pharmaceuticals Inc.
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Amgen Inc
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Merck & Co Inc.
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Boehringer Ingelheim International GmbH
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Cardiology Information System (CIS) Market Size was valued at USD 1.09 billion in 2023 and is expected to reach USD 2.24 billion by 2031 and grow at a CAGR of 9.4% over the forecast period 2024-2031.
The Point of Care Lipid Test Market size was estimated USD 305.53 million in 2023 and is expected to reach USD 444.36 million by 2032 at a CAGR of 4.25% during the forecast period of 2024-2032.
The Synthesis Modules for Radiotracers Market Size was valued at USD 1.20 Billion in 2023 and is expected to reach USD 2.27 Billion by 2032 and grow at a CAGR of 7.66% over the forecast period 2024-2032.
The Anatomic Pathology Market Size was valued at USD 37.97 billion in 2023 and is expected to reach USD 74.64 billion by 2032, growing at a CAGR of 7.86% from 2024-2032.
The Genomic Services Market Size, valued at USD 6.3 billion in 2023, is projected to reach USD 17.5 billion by 2032, at a CAGR of 11.8%. by 2024-2032
The Smart Hospitality Market is anticipated to increase at a CAGR of 30% from 2024 to 2032, from a value of USD 17.55 billion in 2023 and expected to reach USD 186.10 billion by 2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
